TAM
VKTX icon

Titleist Asset Management’s Viking Therapeutics VKTX Stock Holding History

Titleist Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-39,957
Closed -$2.53M – 329
2024
Q3 		$2.53M Sell
39,957
-20,022
-33% -$1.17M 0.36% 68
2024
Q2 		$3.18M Buy
+59,979
New +$3.93M 0.48% 56
2023
Q4 		– Sell
-12,000
Closed -$133K – 236
2023
Q3 		$133K Hold
12,000
– – 0.03% 205
2023
Q2 		$195K Sell
12,000
-2,000
-14% -$41.9K 0.04% 206
2023
Q1 		$233K Buy
+14,000
New +$145K 0.05% 190

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Titleist Asset Management's VKTX Position: Q4 2024 in Review

Titleist Asset Management sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 39,957 shares — an estimated $2.53M sold.

Titleist Asset Management first reported a position in VKTX in Q1 2023 and held it in 5 quarters. The position peaked at $3.18M in Q2 2024. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • Titleist Asset Management reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Titleist Asset Management sold 39,957 Viking Therapeutics shares in Q4 2024, an estimated $2.53M.
  • Titleist Asset Management first reported a position in Viking Therapeutics in Q1 2023 and held it in 5 quarters.
  • Titleist Asset Management's Viking Therapeutics position peaked at $3.18M in Q2 2024.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on Titleist Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.